SCIENTIFIC ADVISORY BOARD

Our Scientific Advisory Board is comprised of thought leaders across a broad range of therapeutic areas and disciplines who have made significant contributions to research, clinical practice, and patient care. Samumed regularly consults and involves these experts in key decisions to help advance the development of our novel therapeutic compounds.

John A. Bergfeld, MD

Senior Surgeon, Department of Orthopaedic Surgery, Cleveland Clinic

John Bergfeld, Emeritus Head of Sports Medicine, is now Senior Surgeon, Department of Orthopaedic Surgery and Director of the Operating Rooms at the Cleveland Clinic.

He is a graduate of Bucknell University where he played football, followed by his Medical Doctor degree at Temple University. He did his internship and orthopaedic residency at Cleveland Clinic.

He served in the US Navy as Chief of Orthopaedics of the United States Naval Hospital (Annapolis, Maryland, USA) and US Naval Academy and aboard the USS Dubuque with rank of Commander MC USNR.

Dr. Bergfeld served as Team Physician for the Cleveland Browns NFL, Cavaliers NBA, Cleveland Ballet, and Baldwin Wallace University.

He served as President of:

  • American College of Sports Medicine (ACSM)
  • American Orthopaedic Society for Sports Medicine (AOSSM)
  • International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)

He has trained over 90 post graduate fellows, both Primary Care (Sports and Exercise Medicine) and Orthopaedic/Sports Medicine (known as the Warthog Society). He has published over 90 peer review articles and book chapters. He has served as visiting professor and presented multiple endowed lectureships in the USA and internationally.

AWARDS

AOSSM

  • Thomas A Brady Community Service Award
  • Mr. Sports Medicine
  • Hall of Fame
  • George Rovere Education Award
  • Godfather – Traveling Fellows

City of Cleveland, Ohio USA

  • Five Star General Award – City of Cleveland
  • Lifetime Achievement Award - Greater Cleveland Sports Commission
  • John H. Budd MD Distinguished Membership Award – Northeast Ohio Academy of Medicine Master Educator Award – Cleveland Clinic Outstanding Alumnus Award
  • Cleveland Clinic
  • Bucknell University – Class of 1960
  • Bucknell University Outstanding Alumni Varsity Athlete- 1991
  • Temple University Medical School

National

  • NFL Trainers Jerry Rhea Award
  • NFL Lifetime Achievement Award
  • USA Rugby Medical Hall of Fame
  • American College of Sports Medicine – Legacy Award
  • NATA Team Physician of the Year
  • Ohio Athletic Trainers Outstanding Physician Award

Honorary Memberships

  • European Society Sports Knee and Arthroscopy (ESSKA)
  • American Medical Society for Sports Medicine (AMSSM)
  • European Federation of Orthopaedic Sports Traumatology (EFOST)
  • International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine (ISAKOS)
  • Spanish Knee and Sports Medicine Society

Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Professor of Medicine, Health Policy and Research, Weill Cornell Medicine

Dr. Allan Gibofsky is Professor of Medicine, Health Policy and Research at Weill Cornell Medicine. He is an Attending Physician and Rheumatologist at The New York Presbyterian Hospital and Hospital for Special Surgery, where he is Co-Director of the Clinic for Inflammatory Arthritis.

Dr. Gibofsky received his undergraduate degree from Brooklyn College of the City University of New York, his MD from Weill Medical College of Cornell University and his law degree from Fordham University. He did his internship in Pathology, followed by a residency in Medicine at New York Hospital. He completed a fellowship in Rheumatology/Immunology jointly at Hospital for Special Surgery and at The Rockefeller University. Dr. Gibofsky has authored or co-authored numerous papers and text chapters, primarily on the immunogenetics of rheumatic diseases and legal aspects of medical practice. He is known for his work on mechanisms of host-microbe interactions in rheumatology, and, in particular for his basic and clinical studies on rheumatic fever as well as for his work on therapeutic strategies in the treatment of inflammatory rheumatic diseases.

Currently Secretary-Treasurer of The New York Rheumatism Association, Dr. Gibofsky is past Chair of the Medical & Scientific Committee of the New York Chapter of The Arthritis Foundation and received their Physicians’ Leadership Award. He also served as a member of the local and national Arthritis Foundation Board of Trustees, and was Chair for Professional Education. Dr. Gibofsky has participated in numerous professional and public education programs, nationally and internationally. He is a past President of the American College of Legal Medicine, and is past Chair of the American Board of Legal Medicine. In 2002, Dr. Gibofsky served as President of The American College of Rheumatology. Dr. Gibofsky is a Jonas Salk Scholar of the City University and was named Alumnus of the Year by Brooklyn College.

Dr. Gibofsky is a Master of the American College of Rheumatology, a Fellow of the American College of Physicians and a Fellow of the American College of Legal Medicine.

Nancy E. Lane, MD

Director, Center for Musculoskeletal Health and Distinguished Professor, University of California at Davis, School of Medicine

Nancy E. Lane, MD is a Distinguished Professor of Medicine, Rheumatology, and Aging Research, Director for the Center for Musculoskeletal Health. She is an internationally recognized scientist in the fields of both osteoporosis and osteoarthritis. Her translational research team has been instrumental in defining the role of glucocorticoids in bone fragility including pioneering a seminal clinical trial to demonstrate that daily injections of the hormone PTH could reverse glucocorticoid-induced osteoporosis. In addition she has uncovered novel genetic variations that predispose individuals to osteoarthritis and has studied novel treatments for osteoarthritis. Her research accomplishments have been recognized by the UC Davis School of Medicine Dean’s Team Science Award (2012), the American College of Rheumatology for the Oscar Gluck Memorial Lecture for outstanding work in Osteoporosis (2011), David Trentham Lectureship and Women in Medicine Lectureship at Harvard Medical School (2013), election to Association of American Physicians (2006) and election to the National Academy of Medicine (2012). Dr. Lane was President of the Board of the United States Bone and Joint Decade (2006-2008), co-led the International Bone and Joint Decade Conference in Washington DC (2010), was elected and served on the council of the American Society of Bone and Mineral Research (2010-2013), and the Orthopedic Research Society, and the Northern California Arthritis Foundation.

Dr. Lane is on the editorial boards of Nature Reviews Rheumatology, Rheumatology (Editorial Board), Seminars in Arthritis and Rheumatism (Associate Editor), Co-editor Arthritis and Rheumatism (2005-2010), and The Journal of Rheumatology; has been named Best Doctors in America annually since 2004, and continues to have an active rheumatology practice.

Rik Lories, MD, PhD

Professor of Rheumatology, Skeletal Biology and Engineering Research Center, KU Leuven

Rik Lories directs the Laboratory for Tissue Homeostasis and Disease that is part of the Skeletal Biology and Engineering Research Center at KU Leuven. He is a consultant physician in the Division of Rheumatology at the University Hospitals Leuven. KU Leuven, the largest and oldest university in Belgium, ranks 40th in the Times Higher Education World 2017 Ranking and tops Reuter’s 2017 ranking of Europe’s most innovative universities.

His research focuses on endogenous tissue responses in the joint with specific attention towards translational questions in chronic arthritis, in particular osteoarthritis, axial spondyloarthritis, and psoriatic arthritis. Currently full Professor (“gewoon hoogleraar”) at KU Leuven, he obtained his medical degree summa cum laude in 1996. He subsequently started specialty training in internal medicine and rheumatology. In 2003, he was certified as rheumatologist. In 2003 he also obtained a PhD in biomedical sciences at KU Leuven. He received PhD (4 years) and Postdoctoral fellowships (6 years) from the Flanders Research Foundation. Rik Lories and his team were the first to demonstrate the key homeostatic role of Wnt signaling in the postnatal joint. The observation that mice in which the Wnt antagonist Frzb has been genetically deleted show increased severity of osteoarthritis pointed the attention of a large research community towards this pathway in particular in osteoarthritis. A recent study on DOT1L in osteoarthritis has identified a novel regulatory mechanism of Wnt signaling in the joint.

He has (co-)authored over 140 publications, including original research reports or reviews in Nature Medicine, Nature Communications, Journal of Clinical Investigation, PNAS, Nature Reviews Rheumatology, Osteoarthritis and Cartilage, Annals of the Rheumatic Diseases and Arthritis and Rheumatology.

Toby Maher, MD, PhD

British Lung Foundation Chair in Respiratory Research; Professor of Interstitial Lung Disease, Imperial College, London; Consultant Physician, Royal Brompton Hospital, London

Toby Maher is British Lung Foundation Chair in Respiratory Research and Professor of Interstitial Lung Disease at Imperial College, London. He also holds a prestigious National Institute for Health Research Clinician Scientist Fellowship and serves as an Honorary Consultant Physician at the Royal Brompton Hospital, London, UK. He leads the Fibrosis Research Group at the National Heart and Lung Institute, Imperial College, London. His research interests include biomarker discovery, clinical trials in ILD and the role of the microbiome and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis (IPF).

Dr. Maher is an Associate Editor of American Journal of Respiratory and Critical Care Medicine. He is on the international advisory board for Lancet Respiratory Medicine and is on the editorial board of the European Respiratory Journal and European Respiratory Review. He has authored over 150 papers and chapters on IPF and ILD.

Timothy McAlindon, MD, MPH

Natalie V. Zucker & Milton O. Zucker Chair of Rheumatology and Professor, Tufts University School of Medicine; Chief, Division of Rheumatology, Tufts Medical Center

Dr. McAlindon has a 20-year research track in the field of osteoarthritis (OA) and currently has set his goals on the development of simple and inexpensive disease-modifying interventions for osteoarthritis. This has brought a focus on the mechanisms of structural progression, its measurement, and comparative effectiveness testing of potential disease modifying interventions. Dr. McAlindon is one of a small number of investigators developing expertise in highly technological image-based evaluation of osteoarthritis structural progression, such as three-dimensional cartilage volume measurement from MRI, trabecular morphometry from MRI, and subchondral DEXA. Dr. McAlindon currently has NIH-funded research grants evaluating the role of bone in OA progression using periarticular DEXA and MRI-based trabecular morphometry, testing the effectiveness of intra-articular corticosteroids on structural progression of knee OA, and developing an integrated parsimonious quantitative knee OA structural damage outcome measure using MRI. Dr. McAlindon has national and international recognition in the field of osteoarthritis, and is a member of the steering committee of the NIH Osteoarthritis Initiative (OAI), co-principal investigator of its Memorial Hospital of Rhode Island clinical site.

William C. Mobley, MD, PhD

Associate Dean for Neurosciences Initiatives, Distinguished Professor of Neurosciences, Florence Riford Chair for Alzheimer Disease Research, University of California San Diego School of Medicine

Dr. Mobley is Associate Dean of Neurosciences Initiatives and Distinguished Professor of Neurosciences at UC San Diego. He serves as Executive Director of UCSD's Down Syndrome Center for Research and Treatment, and holds the Florence Riford Chair of Alzheimer Disease Research. He came to UCSD in June 2009 from Stanford University where he served as the John E. Cahill Family Professor in the Department of Neurology and Neurological Sciences and was founding director of the Neuroscience Institute. Dr. Mobley’s research is focused on degenerative disease of the central nervous system, especially Down syndrome and Alzheimer’s disease.

He and his colleagues have for many years explored the hypothesis that deficient axonal transport of neurotrophic factor signals contribute importantly to the pathogenesis of neurodegeneration.

Dr. Mobley serves as the expert advisor to the Congressional Down Syndrome Caucus. He is Past President of the Association of University Professors of Neurology, of the Professors of Child Neurology, and of the International Society for Developmental Neuroscience. He is a Fellow of the Royal College of Physicians and the American Association for the Advancement of Science. He is a member of the National Academy of Medicine. He received both the Zenith Award and Temple Award from the Alzheimer's Association and the Cotzias Award from the American Academy of Neurology. In 2007 he received the Christian Pueschel Memorial Research Award, and in 2011 was honored with the International Sisley-Jérôme Lejeune Prize by the Jérôme Lejeune Foundation for his research contributions to Down syndrome and genetic intellectual disabilities. He was inducted into the Johns Hopkins University Society of Scholars in 2014.

Daniel D. Von Hoff, MD

Physician in Chief and Director of Translational Research, Translational Genomics Research Institute (TGen)

Daniel D. Von Hoff, M.D., F.A.C.P., is currently Physician in Chief, Distinguished Professor Translational Research at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Senior Consultant, Clinical Investigations for the City of Hope; Chief Scientific Officer for HonorHealth Research Institute; Medical Director of Research, Chief Scientific Officer, US Oncology, and Professor of Medicine, Mayo Clinic.

Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegibm, nab-paclitaxel, nal-IRI, and others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies for patients with pancreatic and other advanced cancers.

Dr. Von Hoff has published more than 690 papers, 140 book chapters and over 1400 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care.

Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world's largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX Oncology, Inc. (acquired by Genzyme after ILEX had two agents, alemtuzumab and clofarabine, approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs - The Journal of New Anticancer Agents; and, past Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.